# Nemolizumab for LS

> **NCT07704775** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Lichen Sclerosus of Vulva

## Interventions

- **BIOLOGICAL:** Nemolizumab 30 mg

## Key facts

- **NCT ID:** NCT07704775
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704775, "Nemolizumab for LS". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*